MMV selects UCT developed anti-malaria molecule for clinical trials
The compound is expected to cure all strains of malaria and stop the transmission of the parasite from person to person as a single-dose malaria cure. The new
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).